Ona Therapeutics advances ONA — 255 through Phase 1a dose escalation as enrollment passes halfway mark
Ysios portfolio company Ona Therapeutics reported rapid enrollment in its Phase 1a dose-escalation trial of lead ADC ONA-255. Aleix Prat was appointed chief medical officer as ONA-255 advances in HR+/HER2-negative advanced breast cancer, metastatic gastric cancer. Jutta Amersdorffer shifted to chief development officer